Barzolvolimab longitudinal UAS7

This is the first plotted pass from the barzolvolimab sponsor-poster and manuscript layer.

What this page shows

• Only explicit numeric values captured from the current local source stack
• No hand-read curve guessing
• A landmark view rather than a full weekly curve, because the current local extraction gives clear week 12 and week 52 response landmarks but not a safely tabulated full UAS7 time series
• A separate post-treatment follow-up callout where the sponsor summary gives a usable high-level week 76 numeric landmark

Plot 1: Week 12 primary-endpoint snapshot

This figure uses explicit LS mean change-from-baseline in UAS7 at week 12 from the AAAAI 2025 CSU poster.

Plot 2: UAS7 <= 6 landmarks

This figure uses explicit week 12 and week 52 responder-rate values from the EADV 2024 congress presentation.

Plot 3: Complete response (UAS7 = 0) landmarks

This figure uses explicit week 12 and week 52 complete-response values from the same phase 2 source layer, with week 12 values also cross-supported by the phase 2 manuscript abstract.

Post-treatment follow-up landmark

The current sponsor-summary layer also gives a usable high-level week 76 complete-response landmark after treatment completion.

Current takeaways

• The clearest explicit numeric barzolvolimab UAS7 backbone right now is landmark-heavy, not curve-heavy.
• By week 12, the 150 mg Q4W and 300 mg Q8W regimens already show much larger UAS7 improvement than placebo on the primary endpoint snapshot.
• By week 52, both active maintained-regimen groups and both transitioned groups show strong rates of UAS7 <= 6 and UAS7 = 0, which fits the broader durability story already visible on the sponsor pages.
• The currently cached sponsor follow-up summary extends that story beyond active dosing, with up to 41% complete response at week 76.

Current gaps

• Exact week-by-week mean UAS7 values are still graph-only in the current local extraction.
• Exact regimen-resolved week 52 mean UAS7 / mean UAS7 CFB is not yet safely tabulated.
• The week 52 values for the former 75 mg and placebo groups are transition-group landmarks after week 16 re-randomization, not unchanged original-arm trajectories.
• The current week 76 value is a sponsor-summary high-level landmark, not a clean regimen-resolved observed-data table.

Local evidence files

• Dataset: data/barzolvolimab_longitudinal_uas7.json
• Notes: data/barzolvolimab_longitudinal_uas7_notes.md
• Source wrappers:
• raw/sponsors/kit/barzolvolimab/aaaai-2025-csu-poster.md
• raw/sponsors/kit/barzolvolimab/eadv-2024-congress-presentation.md
• raw/sponsors/kit/barzolvolimab/ir-press-release-additional-positive-data.md
• raw/publications/pubmed/markdown/PMID41747871.md